Skip to main content
. 2021 May 7;39(21):2359–2366. doi: 10.1200/JCO.20.03093

FIG 1.

FIG 1.

Patient disposition and primary reason for discontinuation from study treatment. The interim analysis set comprised the first 20 evaluable patients who had completed at least two tumor assessments (including the baseline scan and the first on-treatment scan at 6 weeks) or discontinued treatment because of any reason.